Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 6, 2024
Product Development

Clinical report: Akero’s efruxifermin shows deepening treatment effect at 96 weeks

Plus: Novo positions Ozempic to add CKD to label and updates from Apogee, RegenxBio, Ironwood  
BioCentury | May 23, 2023
Deals

Sizing up VectivBio’s takeout premium among '23 M&A deals

Many companies with late-stage assets have commanded triple-digit premiums
BioCentury | Oct 14, 2022
Finance

Oct. 13 Quick Takes: Epic $168M round for Glick’s Odyssey

Plus Dice raises $300M on back of data, Liu’s Prime Medicine seeking $1.6B valuation, and updates from VectivBio, CSPC, Relmada and more
BioCentury | Oct 1, 2022
Product Development

Sept. 30 Quick Takes: Intercept NASH candidate fails Phase III, NDA resubmission on track

Plus Zealand to advance glepaglutide to NDA and updates from Valneva and YS Pharma
BioCentury | Mar 30, 2022
Finance

March 30 Quick Takes: Neuron23 taps Softbank for $100M series C

Plus Akebia dips after FDA issues CRL for vadadustat, and updates from IGM, Adagio and more
BioCentury | Dec 21, 2021
Deals

Happy customer: Sanofi buying Amunix in $1B deal

Bay Area company’s platform helps overcome toxicity issues that have dogged immuno-oncology modalities
BioCentury | Oct 16, 2020
Finance

VectivBio prepping pivotal GI trial with $110M crossover round that could presage IPO

A public listing could be VectivBio’s next financial step now that it has raised $110 million in a crossover round that will fund its planned Phase III trial in short bowel syndrome, as well as
BioCentury | Jan 7, 2020
Company News

VectivBio reunites ex-Therachon management, VCs for short bowel program

VectivBio launches with $35M, hopes to build pipeline beyond the asset it was created to house
BioCentury | May 8, 2019
Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

At the cusp of seeking a public listing, Therachon Holding chose $340M deal with Pfizer and the chance to spin out a new company
Items per page:
1 - 10 of 132